Revvity
RVTYRevvity is a global provider of health science solutions and technologies that support complete workflows from drug discovery to clinical diagnosis.
Earnings
Next report
Aug 4, 2026 (In 3 weeks)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
Profile
Revvity is a global provider of health science solutions and technologies that support complete workflows from drug discovery to clinical diagnosis. The company specializes in translational multi-omics, biomarker identification, imaging, and informatics to accelerate scientific breakthroughs and improve healthcare outcomes. Its value proposition centers on delivering integrated tools and services that facilitate the transition from research to real-world medical cures.
Revvity is a leading global provider in high-growth health science markets, leveraging a massive portfolio of proprietary reagents and automated instrumentation to maintain a strong position in drug discovery and neonatal screening.
Questions, answered.
- What is Revvity's market cap?
- Revvity (RVTY) has a market capitalization of $12.2B and trades on NYSE.
- What is Revvity's revenue and profitability?
- Revvity generated $2.9B in trailing twelve-month revenue with net income of $239.7M, representing a net margin of 8.3%. Gross margin stands at 48.5%, with free cash flow of $492.7M. These figures are based on the Q1 2026 filing.
- Who are Revvity's competitors?
- Revvity's key competitors include Agilent Technologies, Danaher, Thermo Fisher Scientific, and others. These companies compete in similar markets and product categories.
- Who does Revvity partner with?
- Revvity's notable partners include Profluent, Scitara, Medical Device Innovation Consortium, and others.
- What subsidiaries does Revvity have?
- Revvity's subsidiaries include BioLegend, EUROIMMUN, Oxford Immunotec, and others.
- Where is Revvity headquartered?
- Revvity is headquartered in United States of America and employs approximately 11,500 people. It has been publicly traded since 1972.
